Physician profile
Dylan A Estes
NPI 1003278144
$928.52
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.78 · 2020: $146 · 2021: $371 · 2022: $271 · 2023: $14.32 · 2024: $43.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $58.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $58.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $172.39 | 2019-2021 | |
| Abbott Laboratories | $159.88 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $111.73 | 2019-2023 | Farxiga |
| Pfizer INC. | $97.02 | 2020-2022 | |
| Medtronic, INC. | $80.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.28 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $47.72 | 2020 | |
| Novo Nordisk INC | $43.49 | 2020-2021 | |
| Astellas Pharma US INC | $29.60 | 2019-2021 | |
| Amarin Pharma, INC. | $24.55 | 2022 | |
| Abbvie INC. | $20.26 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.45 | 2022 | |
| Eisai INC. | $14.66 | 2020 | |
| Merck Sharp & Dohme LLC | $13.82 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12.53 | 2019 | |
| Glaxosmithkline, LLC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.